Current Report Filing (8-k)
August 01 2019 - 6:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
July 31, 2019
DELMAR PHARMACEUTICALS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including
area code: (604) 629-5989
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock
|
|
DMPI
|
|
The Nasdaq Capital Market
|
Item 4.01 Changes in Registrant’s Certifying Accountant.
On July 31, 2019, DelMar
Pharmaceuticals, Inc. (the “Company”) received notification from Ernst & Young LLP (“E&Y”), the
Company’s independent registered public accounting firm, that, as a result of the relocation of the Company's headquarters
from Vancouver, British Columbia, Canada to San Diego, California, E&Y has declined to stand for re-appointment as the Company’s
independent registered public accounting firm with respect to the audit of the Company’s consolidated financial statements
as of and for the year ending June 30, 2020. E&Y will complete the audit of the Company’s consolidated financial statements
for the year ended June 30, 2019. The decision not to stand for re-appointment was not the result of any disagreements between
the Company and E&Y on any matter of accounting principles or practices, financial statement disclosure, or auditing scope
or procedures.
The Company’s Audit
Committee will accordingly commence the process of evaluating and selecting a replacement firm to serve as the Company’s
independent registered public accounting firm.
E&Y’s report
on the Company’s consolidated financial statements for fiscal year ended June 30, 2018 contained a paragraph stating
that there was substantial doubt about the Company’s ability to continue as a going concern. E&Y’s reports on
the Company’s consolidated financial statements for each of the two most recent fiscal years ended June 30, 2018 and
June 30, 2017 did not contain an adverse opinion or a disclaimer of opinion, and neither such report was qualified or
modified as to uncertainty, audit scope, or accounting principle.
During the fiscal years
ended June 30, 2018 and June 30, 2017, and the subsequent period through July 31, 2019, (i) there were no disagreements
with E&Y on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures,
which disagreement, if not resolved to the satisfaction of E&Y, would have caused E&Y to make reference thereto in its
reports on the financial statements for such years, and (ii) there were no reportable events as described in paragraph (a)(1)(v)
of Item 304 of Regulation S-K, except as described below.
During the audit for the
year ended June 30, 2018, a material weakness in internal control over financial reporting was identified relating to inadequate
segregation of duties over authorization, review and recording of transactions, as well as the financial reporting of such transactions.
During the audit for the year ended June 30, 2017, a material weakness in internal control over financial reporting was identified
relating to inadequate segregation of duties over authorization, review and recording of transactions.
The Company has provided
E&Y with a copy of the above disclosures. A copy of E&Y’s letter to the U.S. Securities and Exchange Commission required
by Item 304(a) of Regulation S-K is included as Exhibit 16.1 to this Report.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DELMAR PHARMACEUTICALS, INC.
|
|
|
|
Date: July 31, 2019
|
By:
|
/s/ Scott Praill
|
|
|
Scott Praill
|
|
|
Chief Financial Officer
|
2
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Sep 2023 to Sep 2024